Heterogeneous expression of erbB-2 messenger RNA in human breast cancer

C. R. King, S. M. Swain, L. Porter, S. M. Steinberg, Marc E Lippman, E. P. Gelmann

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Amplification and mRNA expression of the erbB-2 gene was analyzed in 61 samples of primary human breast carcinoma. In the 57 samples where RNA could be isolated four different expression level groups were identified. Comparison of hybridization signal with that for β-actin revealed that erbB-2 mRNA could not be detected in 6 of 57 samples (11%), was detected at normal levels in 32 of 57 samples (56%), showed 4- to 8-fold overexpression in 8 of 57 samples (14%), and showed 16- to 128-fold overexpression in 11 of 57 samples (19%). Examination of the DNA of the same set of samples revealed 6 of 61 samples (10%) with distinct gene amplification and 6 of 61 samples (10%) with possible gene amplification. The highest levels of erbB-2 overexpression were associated with gene amplification. Samples with 4- to 16-fold overexpression of the erbB-2 mRNA occurred without evident gene abnormalities. There was no association of erbB-2 expression or gene amplification with clinical stage of breast carcinoma or axillary lymph node involvement. The clear amplification of the erbB-2 gene may be associated with a significantly shorter time to treatment failure.

Original languageEnglish
Pages (from-to)4185-4191
Number of pages7
JournalCancer Research
Volume49
Issue number15
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Gene Amplification
Breast Neoplasms
erbB-2 Genes
Messenger RNA
Treatment Failure
Actins
Lymph Nodes
RNA
DNA
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

King, C. R., Swain, S. M., Porter, L., Steinberg, S. M., Lippman, M. E., & Gelmann, E. P. (1989). Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Research, 49(15), 4185-4191.

Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. / King, C. R.; Swain, S. M.; Porter, L.; Steinberg, S. M.; Lippman, Marc E; Gelmann, E. P.

In: Cancer Research, Vol. 49, No. 15, 01.01.1989, p. 4185-4191.

Research output: Contribution to journalArticle

King, CR, Swain, SM, Porter, L, Steinberg, SM, Lippman, ME & Gelmann, EP 1989, 'Heterogeneous expression of erbB-2 messenger RNA in human breast cancer', Cancer Research, vol. 49, no. 15, pp. 4185-4191.
King CR, Swain SM, Porter L, Steinberg SM, Lippman ME, Gelmann EP. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Research. 1989 Jan 1;49(15):4185-4191.
King, C. R. ; Swain, S. M. ; Porter, L. ; Steinberg, S. M. ; Lippman, Marc E ; Gelmann, E. P. / Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. In: Cancer Research. 1989 ; Vol. 49, No. 15. pp. 4185-4191.
@article{8ff258a968934e64b324d10080d49ba9,
title = "Heterogeneous expression of erbB-2 messenger RNA in human breast cancer",
abstract = "Amplification and mRNA expression of the erbB-2 gene was analyzed in 61 samples of primary human breast carcinoma. In the 57 samples where RNA could be isolated four different expression level groups were identified. Comparison of hybridization signal with that for β-actin revealed that erbB-2 mRNA could not be detected in 6 of 57 samples (11{\%}), was detected at normal levels in 32 of 57 samples (56{\%}), showed 4- to 8-fold overexpression in 8 of 57 samples (14{\%}), and showed 16- to 128-fold overexpression in 11 of 57 samples (19{\%}). Examination of the DNA of the same set of samples revealed 6 of 61 samples (10{\%}) with distinct gene amplification and 6 of 61 samples (10{\%}) with possible gene amplification. The highest levels of erbB-2 overexpression were associated with gene amplification. Samples with 4- to 16-fold overexpression of the erbB-2 mRNA occurred without evident gene abnormalities. There was no association of erbB-2 expression or gene amplification with clinical stage of breast carcinoma or axillary lymph node involvement. The clear amplification of the erbB-2 gene may be associated with a significantly shorter time to treatment failure.",
author = "King, {C. R.} and Swain, {S. M.} and L. Porter and Steinberg, {S. M.} and Lippman, {Marc E} and Gelmann, {E. P.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "49",
pages = "4185--4191",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Heterogeneous expression of erbB-2 messenger RNA in human breast cancer

AU - King, C. R.

AU - Swain, S. M.

AU - Porter, L.

AU - Steinberg, S. M.

AU - Lippman, Marc E

AU - Gelmann, E. P.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Amplification and mRNA expression of the erbB-2 gene was analyzed in 61 samples of primary human breast carcinoma. In the 57 samples where RNA could be isolated four different expression level groups were identified. Comparison of hybridization signal with that for β-actin revealed that erbB-2 mRNA could not be detected in 6 of 57 samples (11%), was detected at normal levels in 32 of 57 samples (56%), showed 4- to 8-fold overexpression in 8 of 57 samples (14%), and showed 16- to 128-fold overexpression in 11 of 57 samples (19%). Examination of the DNA of the same set of samples revealed 6 of 61 samples (10%) with distinct gene amplification and 6 of 61 samples (10%) with possible gene amplification. The highest levels of erbB-2 overexpression were associated with gene amplification. Samples with 4- to 16-fold overexpression of the erbB-2 mRNA occurred without evident gene abnormalities. There was no association of erbB-2 expression or gene amplification with clinical stage of breast carcinoma or axillary lymph node involvement. The clear amplification of the erbB-2 gene may be associated with a significantly shorter time to treatment failure.

AB - Amplification and mRNA expression of the erbB-2 gene was analyzed in 61 samples of primary human breast carcinoma. In the 57 samples where RNA could be isolated four different expression level groups were identified. Comparison of hybridization signal with that for β-actin revealed that erbB-2 mRNA could not be detected in 6 of 57 samples (11%), was detected at normal levels in 32 of 57 samples (56%), showed 4- to 8-fold overexpression in 8 of 57 samples (14%), and showed 16- to 128-fold overexpression in 11 of 57 samples (19%). Examination of the DNA of the same set of samples revealed 6 of 61 samples (10%) with distinct gene amplification and 6 of 61 samples (10%) with possible gene amplification. The highest levels of erbB-2 overexpression were associated with gene amplification. Samples with 4- to 16-fold overexpression of the erbB-2 mRNA occurred without evident gene abnormalities. There was no association of erbB-2 expression or gene amplification with clinical stage of breast carcinoma or axillary lymph node involvement. The clear amplification of the erbB-2 gene may be associated with a significantly shorter time to treatment failure.

UR - http://www.scopus.com/inward/record.url?scp=0024411031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024411031&partnerID=8YFLogxK

M3 - Article

C2 - 2568168

AN - SCOPUS:0024411031

VL - 49

SP - 4185

EP - 4191

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -